Pay in 4 interest-free payments of $5.44 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
At USD 1,349 per month list price for Wegovy and USD 1,059 for Zepbound, monthly GLP-1 obesity drug costs create absolute financial barriers for the 62% of obesity patients enrolled in Medicaid, Medicare, or underinsured commercial plans without anti-obesity medication benefits
This leaves more funds available in the older spouses account, which once again, is more likely to result in penalty-free (though not tax-free) distribution of funds needed to cover unqualified, non-medical expenses
Weight-loss drugs like semaglutide may melt fat, but at the cost of muscle mass
Endocr Rev, 33(5), 712746
Ethics declarations Conflict of interest Nathalie Goemans was principle investigator for PRO051
US$ 27.93
US$ 20.85
US$ 20.42
